BioCardia (NASDAQ:BCDA – Get Free Report) and Synlogic (NASDAQ:SYBX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk.
Insider & Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 17.4% of BioCardia shares are held by insiders. Comparatively, 2.6% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares BioCardia and Synlogic”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioCardia | $60,000.00 | 273.78 | -$8.23 million | ($0.64) | -1.70 |
| Synlogic | $8,000.00 | 1,837.35 | -$23.36 million | ($0.06) | -20.00 |
BioCardia has higher revenue and earnings than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than BioCardia, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
BioCardia has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for BioCardia and Synlogic, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| Synlogic | 1 | 0 | 0 | 0 | 1.00 |
BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 2,204.15%. Given BioCardia’s stronger consensus rating and higher probable upside, equities analysts plainly believe BioCardia is more favorable than Synlogic.
Profitability
This table compares BioCardia and Synlogic’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -569.36% | -183.15% |
| Synlogic | N/A | -26.47% | -18.00% |
Summary
BioCardia beats Synlogic on 8 of the 13 factors compared between the two stocks.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
About Synlogic
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
